Beschreibung:
<jats:p>
Anti-CD20 antibody therapy is used for both cancer and autoimmune disease but has been shown to be associated with
<jats:named-content content-type="genus-species">Pneumocystis</jats:named-content>
pneumonia in humans. This study shows that low-dose subcutaneous anti-CD20 can modulate B cell populations without grossly perturbing fungal immunity against
<jats:named-content content-type="genus-species">Pneumocystis</jats:named-content>
lung infection.
</jats:p>